![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif)
VEGFR-2 inhibitor peptide CT-322 A highly specific, vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist with potential antiangiogenic activity. Derived from human fibronectin, VEGFR-2 inhibitor peptide CT-322 may block the activation of VEGFR-2 by all known activating ligands, thereby inhibiting the growth of new tumor blood vessels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif)
US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif) | Angiocept | | ![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif) | CT-322 | | ![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115004313im_/http://www.cancer.gov/images/spacer.gif) |